Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1

Status

Active not recruiting 26Completed 25Recruiting 19Terminated 10Unknown 7Not yet recruiting 5Withdrawn 4

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Gynecologic 3Thoracic 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 4Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency 1Breast Neoplasms 1

Interventions

Trastuzumab 25Carboplatin 20Paclitaxel 19pertuzumab 18pyrotinib 17Cyclophosphamide 17Capecitabine 16trastuzumab deruxtecan 15Docetaxel 15Radiotherapy 13Standard of Care 12Fulvestrant 12Drug Therapy 12dalpiciclib 11Letrozole 11pembrolizumab 9Epirubicin 9sacituzumab govitecan 8palbociclib 8exemestane 8eribulin 8Anastrozole 8Injections 7Doxorubicin 7130-nm albumin-bound paclitaxel 7toripalimab 6abemaciclib 6Tamoxifen 6Specimen Handling 6Neoadjuvant Therapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × olaparib × Breast × Clear all
NCT07486687 2026-03-20

PLANET

The Netherlands Cancer Institute

Phase 3 Not yet recruiting
1,000 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05128734 2025-12-15

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

AHS Cancer Control Alberta

Phase 2 Not yet recruiting
40 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07187674 2025-09-23

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Harbin Medical University

Phase NA Not yet recruiting
20 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07113964 2025-08-11

QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
79 enrolled
Breast

Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency

NCT07005583 2025-06-05

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
46 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡